Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy

Objective:To confirm the effect of postmenopausal hypoestrogenism and hormone therapy (HT) on body composition and serum leptin levels. Design:Prospective, longitudinal study evaluating body composition (body mass index, and total and percent fat mass and lean mass measured at the arms, legs and trunk) with dual-energy x-ray absorptiometry and serum leptin levels by radioimmunoassay in 44 healthy postmenopausal women randomized to receive either no treatment (n = 22) or transdermal 17β-estradiol (50 μg/day) in continuous regimen and nomegestrol (5 mg/day for 12 days/month) in a sequential regimen (n = 22). Results:One year after the beginning of the study, in untreated women, total and trunk fat mass and percent fat were significantly increased, whereas trunk lean mass was significantly decreased. On the contrary, women treated with HT did not show any significant difference in body composition parameters. In untreated women, serum leptin levels were significantly increased at the end of the study in comparison with baseline values. Serum leptin levels at the other times evaluated were not significantly different from baseline values. In women treated with HT, serum leptin levels did not show significant changes throughout the study. Conclusions:Untreated postmenopausal women show an increase in total and percent fat mass and a centralization of fat distribution. Serum leptin levels parallel this increase, resulting in significantly higher levels 1 year after the study. Women treated with HT are protected against these changes. This may represent a protective mechanism against cardiovascular diseases.

[1]  C. Christiansen,et al.  Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. , 1991, Metabolism: clinical and experimental.

[2]  E. Poehlman,et al.  Changes in Energy Balance and Body Composition at Menopause: A Controlled Longitudinal Study , 1995, Annals of Internal Medicine.

[3]  E. Barrett-Connor,et al.  Long-term postmenopausal hormone use, obesity, and fat distribution in older women. , 1996, JAMA.

[4]  E. Tai,et al.  Body fat distribution and cardiovascular risk in normal weight women. Associations with insulin resistance, lipids and plasma leptin , 2000, International Journal of Obesity.

[5]  E. Poehlman,et al.  Menopause‐associated changes in plasma lipids, insulin‐like growth factor I and blood pressure: a longitudinal study , 1997, European journal of clinical investigation.

[6]  J. Schenker,et al.  Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. , 1995, Fertility and sterility.

[7]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[8]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[9]  C. Christiansen,et al.  Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women. , 1989, Metabolism: clinical and experimental.

[10]  S. Phinney,et al.  Gender differences in plasma leptin concentrations , 1996, Nature Medicine.

[11]  B. Lees,et al.  17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. , 2001, Maturitas.

[12]  E. Poehlman.  Menopause, energy expenditure, and body composition , 2002, Acta obstetricia et gynecologica Scandinavica.

[13]  J. Seidell,et al.  Fat distribution in relation to age, degree of obesity, smoking habits, parity and estrogen use: a cross-sectional study in 11,825 Dutch women participating in the DOM-project. , 1990, International journal of obesity.

[14]  R. V. Van Pelt,et al.  Contributions of total and regional fat mass to risk for cardiovascular disease in older women. , 2002, American journal of physiology. Endocrinology and metabolism.

[15]  M. Sheehan,et al.  The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass. , 1995, American journal of obstetrics and gynecology.

[16]  S. Haffner,et al.  Leptin concentrations in women in the San Antonio Heart Study: effect of menopausal status and postmenopausal hormone replacement therapy. , 1997, American journal of epidemiology.

[17]  A. Genazzani,et al.  Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  C. Nappi,et al.  Effects of sex steroid hormones and menopause on serum leptin concentrations , 2002, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[19]  R. Leibel,et al.  Effects of gender, body composition, and menopause on plasma concentrations of leptin. , 1996, The Journal of clinical endocrinology and metabolism.

[20]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[21]  F. Chehab,et al.  Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin , 1996, Nature Genetics.

[22]  M. K. James,et al.  Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. , 1997, The Journal of clinical endocrinology and metabolism.

[23]  Steven R Smith,et al.  A leptin dose-response study in obese (ob/ob) and lean (+/?) mice. , 1998, Endocrinology.

[24]  A. Genazzani,et al.  Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. , 2001, Maturitas.

[25]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[26]  B. Lees,et al.  Sex- and menopause-associated changes in body-fat distribution. , 1992, The American journal of clinical nutrition.

[27]  M. K. James,et al.  Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. , 1997, The Journal of clinical endocrinology and metabolism.

[28]  G. Frühbeck,et al.  Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. , 2002, Clinical biochemistry.

[29]  B. Lees,et al.  17β-Estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women , 2001 .

[30]  N. Sato,et al.  Estrogen increases in vivo leptin production in rats and human subjects. , 1997, The Journal of endocrinology.

[31]  G. Bifulco,et al.  Effects of bilateral ovariectomy and postoperative hormonal replacement therapy with 17&bgr;-estradiol or raloxifene on serum leptin levels , 2003, Menopause.

[32]  C. Nappi,et al.  Serum Leptin Levels in Postmenopausal Women: Effects of Transdermal Hormone Replacement Therapy , 2000, Menopause.

[33]  Hongping,et al.  Leptin is a metabolic signal to the reproductive system. , 1996, Endocrinology.